New Dual-Action drug shows promise for untreatable liver cancer
NCT ID NCT05432492
First seen Mar 04, 2026 · Last updated May 12, 2026 · Updated 9 times
Summary
This study tested a new drug called AK112 in 40 people with advanced liver cancer that could not be removed by surgery. The drug targets two proteins (PD-1 and VEGF) to help the immune system fight the cancer and cut off its blood supply. The main goals were to see if the drug is safe and how many patients' tumors shrank or disappeared.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China
Conditions
Explore the condition pages connected to this study.